Place of magnesium sulfate in cardiopulmonary resuscitation. A systematic review and meta-analysis by Ludwin, Kobi et al.
Disaster and Emergency Medicine Journal 
2020, Vol. 5, No. 4, 182–189
DOI: 10.5603/DEMJ.a2020.0041
Copyright © 2020 Via Medica 
ISSN 2451–4691
182 Copyright © 2020 Via Medica, ISSN 2451–4691
original article
Place of magnesium sulfate in 
cardioPulmonary resuscitation. a systematic 
review and meta-analysis
Kobi Ludwin1 , Jacek Smereka1,2 , Milosz J. Jaguszewski3 , Krzysztof J. Filipiak4 ,  
Jerzy R. Ladny1,5 , Lukasz Szarpak1,6,7 , Sylwia Wozniak8, Togay Evrin9
1Polish Society of Disaster Medicine, Warsaw, Poland 
2Department of Emergency Medical Service, Wroclaw Medical University, Wroclaw, Poland 
3First Department of Cardiology, Medical University of Gdansk, Poland 
4First Chair and Department of Cardiology, Medical University of Warsaw, Poland 
5Department of Emergency Medicine, Medical University of Bialystok, Poland 
6Bialystok Oncology Center, Bialystok, Poland 
7Maria Sklodowska-Curie Medical Academy in Warsaw, Poland 
8Students Research Club, Maria Sklodowska-Curie Medical Academy in Warsaw, Poland 
9Department of Emergency Medicine, Ufuk University Medical Faculty, Dr Ridvan Ege Education and Research Hospital, Ankara, Turkey
ABSTRACT
INTRODUCTION: Sudden cardiac arrest treatment is challenging, And the effectiveness of resuscitation pro-
cedures — especially in pre-hospital conditions — is low. The purpose of this meta-analysis is to investigate 
the effects of magnesium sulfate (MgSO4) in cardiac arrest on the return of spontaneous circulation (ROSC) 
and survival to hospital discharge.
MATERIAL AND METHODS: We searched in MEDLINE, EMBASE, Scopus, and ClinicalTrials.gov, Web of Science 
up to May 25, 2020, and we conducted a systematic review and meta-analysis. We synthesized results by 
using mean differences, and odds ratios. The overall incidence and outcome of cardiac arrest were assessed 
using a random-effects meta-analysis.
RESULTS: A total of 5 eligible studies were included in this meta-analysis. Survival to discharge was higher in 
magnesium sulfate group compared to placebo group (9,5% vs. 8.2% respectively; OR = 1.17; 95% CI: 0.61, 
2.23; p = 0.64). Higher survival rate to hospital admission was observed in the placebo group — 26.9% com-
pared to the group where magnesium was administered — 25.7% (OR = 0.93; 95% CI: 0.59, 1.47; p = 0.77.
CONCLUSIONS: In conclusion, this meta-analysis indicates no statistically significant benefit of resuscitation with 
magnesium sulfate compared to the placebo. Thus, due to the low number of studies we recommend future ran-
domized controlled trials to identify which anti-arrhythmic drug we should use on shock-refractory cardiac arrest.
KEY WORDS: magnesium sulfate, antiarrhythmic agents, cardiopulmonary resuscitation, advanced cardiovas-
cular life support, meta-analysis, a systematic review
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INTRODUCTION 
Magnesium is an important cofactor of several crit-
ical enzymes in the human body and is used both 
in pre-hospital care and in hospital wards. Assorting 
to the Deheinzelin et al. study incidence of hypo-
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magnesemia was reported in up to 65% in critically 
ill patients [1].
The therapeutic effect of magnesium sulfate is 
based on the antagonistic effect concerning calci-
um ions (Ca2+) or blocking the release of catecho-
lamines. This is due to the stabilizing effect of cell 
membranes by forming complexes with membrane 
phospholipids, which reduces the fluidity and perme-
ability of cell membranes. MgSO4 also presents an ef-
fect on neuromuscular conduction by increasing the 
excitability threshold, which results in a decrease in 
the contractility of both striated and smooth muscles. 
According to the characteristics of the drug 
MgSO4 is used in the treatment of magnesium de-
ficiency: a) confirmed hypomagnesemia (e.g. In 
children with primary congenital hypomagnesemia, 
adults with malabsorption syndrome after persistent 
diarrhea, chronic alcoholism or prolonged parenteral 
nutrition); b) in the prevention and treatment of hypo-
magnesemia in patients who are parenterally fed ex-
clusively; c) in the control and prevention of seizures in 
severe pre-eclampsia; d) in the control and prevention 
of recurrence of eclampsia; e) in torsade de pointes.
The use of MgSO4 requires medical personnel 
to monitor the patient as well as monitor blood 
magnesium levels. If magnesium concentration 
is > 6.2 mmol/l (15 mg%), bradycardia may occur, 
while if magnesium concentration is > 7.5 mmol/l 
(18 mg%), conductivity disturbances and cardiac 
arrest due to hypermagnesemia may occur. 
The advantages of administering magnesium in 
deficient states are known, but the benefits of rou-
tine administration of this element during a cardiac 
arrest have not been documented. However, some 
studies have shown that magnesium can be benefi-
cial in resistant VF. Magnesium has well-known elec-
trophysiological effects and normal concentrations 
are required to maintain normal cardiac conduction 
and rhythm. These actions of magnesium sulfate 
make it applicable in shock-resistant VF when hypo-
magnesemia is suspected; ventricular tachyarrhyth-
mia when hypomagnesemia is suspected; torsades 
de pointes (polymorphic ventricular tachycardia) or 
digoxin poisoning. In stock-resistant VF, an initial 
dose of 2 g should be administered intravenously 
(4 ml of 50% magnesium sulfate = 8 mmol) to the 
peripheral vascular bed in 1–2 minutes. It can be 
repeated after 10–15 minutes. 
Therefore, we performed an updated meta-anal-
ysis of randomized controlled trials, addressing 
whether magnesium sulfate, compared with pla-
cebo, improves survival outcome and good neuro-
logical outcome (Cerebral Performance Categories 
Scale, CPC 1, 2) in adult patients with cardiac arrest. 
Besides, we analyzed outcomes of subgroups ac-
cording to the location of arrest (out-of-hospital or 
in-hospital cardiac arrest). The primary objective was 
to determine whether magnesium sulfate results in 
better survival to discharge outcomes.
MATERIAL AND METHODS 
This systematic review and meta-analysis adhered to 
the Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses (PRISMA) guidelines [2] and is 
part of a larger systematic review that evaluated 
pharmacological effectiveness in cardiac arrest. Be-
fore starting the study, all authors agreed on the 
analysis methods and the inclusion and exclusion cri-
teria to be applied. The protocol of this meta-analy-
sis study has not been registered.
Search strategy
We searched Medline, PubMed, EMBASE, Scopus, 
Web of Science, and the Cochrane Database of Sys-
tematic Reviews from inception to 25 May 2020. The 
search terms were “magnesium” or “MgSO4” and 
“cardiac arrest” or “IHCA” or “OHCA” or “ventricu-
lar fibrillation” or “VF” or “ventricular tachycardia” 
or “VT” or “CPR” or “cardiopulmonary resuscita-
tion” or “sudden cardiac death” or “survival rate” or 
“mortality” or “return of spontaneous circulation”. 
Only articles published in English were considered. 
Additionally, relevant clinical guidelines, systematic 
reviews, meta-analysis, and references of relevant 
publications were used to identify additional studies. 
Inclusion criteria and exclusion criteria
Studies were included if they met the following 
eligibility criteria: a) evaluated adults aged at least 
18 years old with cardiac arrest; b) compared mag-
nesium sulfate with placebo; c) reported outcomes 
of interest; and d) were English language articles. We 
contacted the corresponding authors to obtain fur-
ther information when these values could not be 
obtained from the reported data. Review articles, 
letters to the editor, conference papers, guidelines, 
editorials, and case reports were excluded. 
Data extraction 
Two independent reviewers (K. L. and J. S.) screened 
the titles and abstracts of all citations using pre-
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specified inclusion and exclusion criteria. Studies 
included by either reviewer were retrieved for full-
text screening. The same reviewers then screened 
the full-text version of eligible references. The fol-
lowing data were extracted from the studies: the 
first author’s name, year of publication, a region 
of publication, number of patients, sex (male), 
age of patients. The rate of survival to hospi-
tal discharge was considered as the primary out-
come. ROSC, survival with favorable neurological 
outcomes were also analyzed as outcome varia-
bles. Discrepancies between the reviewers were 
resolved through discussion. If consensus could 
not be reached, a third reviewer (L. S.) resolved 
the disagreement.
Quality assessment
Two authors (L. S. and J. S.) estimated the risk 
of bias. They evaluated the risk of bias of the in-
cluded studies using Cochrane Collaboration “risk 
of bias” tool Review Manager software, version 
5.3 (RevMan; Cochrane Collaboration, Oxford, UK) 
for randomized trials. According to the Higgins 
assessing the risk of bias guidelines [3] and pre-
vious meta-analysis the following domains were 
evaluated for RCTs: random sequence generation 
(selection bias), allocation concealment (selection 
bias), blinding of participants and personnel (per-
formance bias), blinding of outcome assessment 
(detection bias), incomplete outcome data (attri-
tion bias), selective reporting (reporting bias) and 
other bias [4]. Each was graded “yes”, “no”, or 
“unclear”, which reflected a high risk of bias, low 
risk of bias, and uncertain bias, respectively. The 
review authors’ judgments about each risk of bias 
item are provided in Supplementary digital file. The 
overall risk of bias for the study was rated ‘low’ if 
7 or more domains were rated low, ‘moderate’ if 
4 to 6 domains were rated low, and ‘high’ if 1 to 
3 domains were rated low. 
Statistical analysis
All statistical analyses were conducted using Review 
Manager version 5.3 (Cochrane Collaboration, Ox-
ford, UK). A random-effects model was used to es-
timate the outcomes among cardiac arrest patients 
who received magnesium. The Mantel-Haenszel 
method was used to pool dichotomous data and to 
compute pooled odds ratios (ODs) with 95% con-
fidence intervals (CIs). The inverse variance method 
was used to pooled continuous data and to calcu-
late weight mean differences with 95% CIs. When 
the continuous outcome was reported in a study as 
median, range, and interquartile range, we estimat-
ed means and standard deviations using the formula 
described by Hozo et al. [5]. Statistical heterogene-
ity across studies was assessed with the I2 statistic, 
where values of 25%, 50%, and 75% represented 
the cut-off points for low, moderate, and high lev-
els of heterogeneity, respectively [6]. All statistical 
tests were two-sided and were considered when 
p < 0.05.
Subgroup analyses stratified by cardiac arrest 
place (in-hospital or out-of-hospital) were conduct-
ed to investigate potential sources of heterogeneity 
across subgroups. We performed sensitivity analy-
ses by omitting one study at a time to assess the 
influence of any single study on the pooled survival 
rate estimates.
RESULTS
On May 25, 2020, 387 studies were retrieved from 
our literature search for review. After removing 
duplicate articles, we further excluded 289 articles 
based on titles and abstracts. A total of 22 articles 
were selected for further full-text assessment. After 
retrieving the full text for evaluation in detail, 17 ar-
ticles were excluded because they did not meet our 
outcomes. Finally, a total of five studies were includ-
ed in the present meta-analysis [7–11] (Fig. 1).
Characteristics and quality of the studies 
included
The characteristics of the 5 included studies are 
shown in Table 1. Three of those studies were con-
ducted in the USA [7, 10, 11], one in Australia [8], 
and one in the UK [9]. The year of publication 
ranged from 1997 to 2002. In total, 449 cardiac 
arrest patients were involved in this study. Five stud-
ies reported the incidence of return of spontaneous 
circulation [7–11], four the incidence of survival to 
hospital admission (or 24 hours survival) [7–9, 11], 
five studies survival to hospital discharge [7–11] 
and one study survival with favorable neurological 
outcome [10].
Survival to discharge
Survival to discharge was reported by five trials [7–11] 
and was higher in magnesium sulfate group com-
pared to placebo group (9,5% vs. 8.2% respectively; 
OR = 1.17; 95% CI: 0.61, 2.23; p = 0.64) (Fig. 2). 
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In out-of-hospital cardiac arrest survival to hospi-
tal discharge for magnesium was 3.6% and was 
1.5% higher than in the placebo group (OR = 1.60; 
95% CI: 0.40, 6.43; p = 0.51). In in-hospital car-
diac arrest group survival to hospital discharge in 
magnesium sulfate group and placebo group var-
ied and amounted to 17.2% vs. 15.9% respectively 
(OR = 1.07; 95% CI: 0.51, 2.23; p = 0.86). 
Return of spontaneous circulation
Five studies reported a return of spontaneous circu-
lation [7–11]. In pooled analysis range of ROSC for 
FIgURE 1. Flow diagram showing stages of database searching and study selection.
Table 1. Baseline demographic data of the included studies
Study Country Study design
MgSO4 group Control group
n Age Sex, male n Age Sex, male
Allegra et al. 2001 USA Double-blinded RCT 58 65 (13) 33 (56.9%) 58 65 (14) 27 (46.6%)
Fatovich et al. 1997 Australia Double-blinded RCT 31 64 (11.1) 25 (80.6%) 36 65 (12.8) 31 (86.1%)
Hassan et al. 2002 United Kingdom Double-blinded RCT 52 65 (15) 37 (71.2%) 53 67 (12) 37 (55.2%)
Miller et al. 1995 USA Open label 
randomized study
23 72.3 NR 33 73.6 NR
Thel et al. 1997 USA Open label 
randomized study
76 61.8 (3.5) 46 (60.5%) 80 67 (2.7) 43 (53.8%)
NR — Not reported; RCT — Randomized controlled trial
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magnesium was 32.5% and was slightly higher than 
for placebo — 31.3% (OR = 1.21; 95% CI: 0.66, 
2.21; p = 0.73) (Fig. 3). Subgroup analysis showed 
that for out-of-hospital cardiac arrest the efficacy 
of ROSC was observed in 20.3% of cases in the 
magnesium group and 17.5% in the placebo group 
(OR = 1.21; 95% CI: 0.66, 2.21; p = 0.53). In in-hos-
pital cardiac arrest the rate of ROSC was 48.6% 
vs. 48.7% respectively (OR = 1.09; 95% CI: 0.46, 
2.59; p = 0.84). 
Survival to hospital admission/24 hours
Four studies reported survival to hospital admission 
or 24 hours survival [7–9, 11]. Higher survival rate 
was observed in the placebo group — 26.9% com-
pared to the group where magnesium was admin-
FIgURE 2. Forest plot of survival to discharge in magnesium vs. non-magnesium groups. The center of each square represents the odds  
ratio for individual trials, and the corresponding horizontal line stands for a 95% confidence interval. The diamonds represent pooled results.
FIgURE 3. Forest plot of return of spontaneous circulation in magnesium vs. non-magnesium groups. The center of each square repre-
sents the odds ratio for individual trials, and the corresponding horizontal line stands for a 95% confidence interval. The diamonds repre-
sent pooled results.
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istered — 25.7% (OR = 0.93; 95% CI: 0.59, 1.47; 
p = 0.77) (Fig. 4). 
Survival with favorable neurological outcome
Only study by Miller et al. [10] reported survival 
to hospital discharge with favorable neurologi-
cal outcome. This outcome was comparable be-
tween the groups magnesium sulfate vs. placebo 
(3.4% vs. 3.0%; OR = 1.14; 95% CI: 0.07, 19.13; 
p = 0.93). 
DISCUSSION
We conducted a systematic review and meta-anal-
ysis to evaluate the association magnesium sulfate 
with survival after out-of-hospital as well as in-hos-
pital cardiac arrest.
Magnesium sulphate has a wide range of appli-
cations in emergency medicine. It is mainly used in 
ventricular fibrillation or shock-resistant tachycardia 
as well as in other life-threatening tachyarrhythmias, 
especially when they result from hypomagnesemia, 
in torsades de pointes [12, 13] or in situations where 
there is a suspicion of cardiac arrest due to poison-
ing with cardiac glycosides [14], in acute asthma 
[15, 16] or acute stroke [17, 18].
Magnesium itself is a component of many en-
zymatic systems that determine the production of 
energy in the muscles. It is also an antagonist of cal-
cium ions causing a decrease in the systolic strength 
and heart rate while improving the systolic activity 
of the myocardium [18]. 
Magnesium sulfate is considered an antiarrhyth-
mic drug. Currently, there is no unanimous approach 
to its use during cardiopulmonary resuscitation. In 
a trial by Fatovich et al. high dose of magnesium as 
first-line drug therapy for out-of-hospital cardiac ar-
rest was not associated with significantly improved 
survival [8]. The Hassan et al study also reached 
similar conclusions [9].
A study performed by Upala et al. found a strong 
association between hypomagnesemia and in-
creased mortality in ICU patients [20]. In turn, 
a study by Johnson et al. relating to the evaluation 
of the correlation between cord blood magnesium 
concentration and the effectiveness of resuscitation 
concerning neonatal resuscitation showed no rela-
tionship between cord blood Mg and delivery room 
resuscitation [21].
An increase in adrenaline levels during resuscita-
tion may increase the release of magnesium, which 
creates a toning effect utilizing negative feedback 
resulting in the release of magnesium from the stor-
age pool and thus lowering the adrenaline levels as 
a final result [22, 23]. Magnesium ions, as already 
mentioned in the introduction, influence the ac-
tivity of enzymes regulating carbohydrate metab-
olism and modulate the supply of glucose to nerve 
cells. Magnesium ions also have a stabilizing effect 
on the cell membranes of thrombocytes, thus reduc-
ing platelet aggregation [24, 25]. 
The present study has several potential limita-
tions. We only these studies published in English 
were included in this meta-analysis and studies in 
other languages were omitted. Another limitation 
is the small number of studies on the effective-
ness of magnesium sulfate during cardiopulmonary 
resuscitation.
CONCLUSIONS
In conclusion, this meta-analysis indicates no sta-
tistically significant benefit of resuscitation with 
magnesium sulfate compared to the placebo. Thus, 
due to the low number of studies we recommend 
future randomized controlled trials to identify which 
FIgURE 4. Forest plot of survival to hospital admission in magnesium vs. non-magnesium groups. The center of each square represents 
the odds ratio for individual trials, and the corresponding horizontal line stands for a 95% confidence interval. The diamonds represent 
pooled results.
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anti-arrhythmic drug we should use on shock-refrac-
tory cardiac arrest.
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